📰 In Process Research News
Page 2 - In Process Research News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from In Process Research. Real-time updates on events, politics, business and more.
March 2, 2023
$ million Gross to Net Adjustment 19% - 20% 21% - 21.5% Conference Call Puma Biotechnology will host a conference call to report its fourth quarter and full year 2022 financial results... | March 2, 2023
February 13, 2023
$9.2M in net product revenue from VTAMA reported for the quarter ended December 31, 2022, with nearly 100,000 VTAMA prescriptions written by approximately 8,600 unique prescribers since launchVTAMA... | February 13, 2023
November 14, 2022
14.11.2022 - – Cash Position of $21.3 Million as of September 30, 2022 – – Hosting Phase 3 REGAL Study Update Webcast Today at 8:30 a.m. ET – NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or ...
November 4, 2022
Raises FY 2022 NERLYNX Net Product Revenue GuidanceLOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2022. Unless otherwise stated, all comparisons are for the third quarter of 2022 compared to the...
June 28, 2022
Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical entity launched for plaque psoriasis in
March 1, 2022
WALTHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV) a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central
November 1, 2021
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2021. "Our third...
April 15, 2021
NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update Acquisition of ANA Therapeutics provides late-stage COVID-19 clinical development program with numerous key inflection points in 2021 News provided by Share this article BOSTON, April 15, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neurop...